A detailed history of Verition Fund Management LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 47,195 shares of EXEL stock, worth $1.71 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
47,195
Holding current value
$1.71 Million
% of portfolio
0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $1.04 Million - $1.3 Million
47,195 New
47,195 $1.22 Million
Q3 2023

Nov 14, 2023

BUY
$19.04 - $22.74 $85,984 - $102,693
4,516 Added 18.57%
28,839 $630,000
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $199,415 - $224,768
10,975 Added 82.22%
24,323 $464,000
Q1 2023

May 15, 2023

SELL
$16.3 - $19.41 $211,769 - $252,174
-12,992 Reduced 49.32%
13,348 $259,000
Q4 2022

Feb 14, 2023

SELL
$14.96 - $17.39 $170,020 - $197,637
-11,365 Reduced 30.14%
26,340 $422,000
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $385,555 - $547,597
24,589 Added 187.47%
37,705 $591,000
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $228,743 - $303,766
13,116 New
13,116 $273,000
Q3 2021

Nov 15, 2021

SELL
$16.3 - $21.14 $231,769 - $300,589
-14,219 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$17.95 - $25.56 $255,231 - $363,437
14,219 New
14,219 $259,000
Q4 2019

Feb 14, 2020

SELL
$15.15 - $18.89 $316,468 - $394,593
-20,889 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$17.68 - $22.65 $177,966 - $227,994
10,066 Added 93.01%
20,889 $369,000
Q2 2019

Aug 14, 2019

SELL
$18.93 - $24.75 $897,755 - $1.17 Million
-47,425 Reduced 81.42%
10,823 $231,000
Q1 2019

May 15, 2019

BUY
$19.6 - $24.76 $243,294 - $307,345
12,413 Added 27.08%
58,248 $1.39 Million
Q4 2018

Feb 14, 2019

BUY
$13.65 - $21.8 $469,600 - $749,985
34,403 Added 300.94%
45,835 $902,000
Q3 2018

Nov 15, 2018

BUY
$15.87 - $22.4 $15,139 - $21,369
954 Added 9.1%
11,432 $203,000
Q2 2018

Aug 15, 2018

SELL
$18.56 - $22.45 $153,899 - $186,155
-8,292 Reduced 44.18%
10,478 $225,000
Q1 2018

May 16, 2018

BUY
$22.15 - $31.89 $239,175 - $344,348
10,798 Added 135.45%
18,770 $416,000
Q4 2017

Feb 15, 2018

SELL
$24.23 - $30.93 $306,654 - $391,450
-12,656 Reduced 61.35%
7,972 $242,000
Q3 2017

Nov 14, 2017

BUY
$23.35 - $29.24 $481,663 - $603,162
20,628
20,628 $500,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.